{"nctId":"NCT01237327","briefTitle":"Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer","startDateStruct":{"date":"2001-11"},"conditions":["Metastatic Breast Cancer"],"count":84,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Megestrol acetate"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: exemestane (Aromasin)"]}],"interventions":[{"name":"Megestrol acetate","otherNames":["Megace"]},{"name":"exemestane (Aromasin)","otherNames":["Aromasin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previous participation in study 971-ONC-0028-080.\n\nExclusion Criteria:\n\n* Subjects who had not previously participated in study 971-ONC-0028-080.","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival in months measured from date of starting treatment in core study to date of death for any reason.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"16.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"Percentage of participants achieving an objective response (OR) defined as complete response (CR) or partial response (PR) out of the total number of participants randomized in each treatment group","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DR)","description":"Duration of objective response (complete response \\[CR\\] or partial response \\[PR\\]) calculated from date objective response was first documented to date of progressive disease. For subjects proceeding from PR to CR, the onset of PR was taken as the onset of objective response.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"35.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Progression (TTP)","description":"TTP = time between first day of study treatment and date of documented disease progression, or date of tumor-related death in the absence of previously documented progressive disease (PD). PD defined as a 25% or greater increase in size of 1 or more lesions compared to smallest previous assessment, or appearance of new lesion, or unequivocal worsening of bone lesions, or progression of nonevaluable lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure (TTF)","description":"TTF = time between first day of study treatment and date of diagnosis of progression, withdrawal from study treatment for any reason, administration of other antitumor treatment, or death from any cause, whichever was the earliest event.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":41},"commonTop":["Cough","Sweating increased","Nausea","Weight increased","Fatigue"]}}}